For the year ending 2025-12-31, ALLR made $320K in revenue. -$11,231K in net income. Net profit margin of -3509.69%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenue | 320 | |||
| Research and development | 6,601 | |||
| Impairment of intangible assets | 0 | |||
| General and administrative | 6,324 | |||
| Total operating expenses | 12,925 | |||
| Loss from operations | -12,605 | |||
| Interest income | 801 | |||
| Interest expenses | 185 | |||
| Foreign exchange gains (losses) | 757 | |||
| Change in fair value adjustment of warrant derivative liabilities | -1 | |||
| Total other income | 1,374 | |||
| Loss before income tax expense (benefit) | -11,231 | |||
| Income tax expense (benefit) | 0 | |||
| Net loss | -11,231 | |||
| Deemed dividends on preferred stock-Series APreferred Stock | 0 | |||
| Deemed dividends on preferred stock-Redeemable Series AConvertible Preferred Stock | 0 | |||
| Gain on extinguishment of series a preferred stock-Series APreferred Stock | 0 | |||
| Net loss attributable to common stockholders | -11,231 | |||
| Basic EPS | -0.78 | |||
| Basic Average Shares | 14,378,942 | |||
Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc. (ALLR)